Printer Friendly

Heptares Therapeutics' calcitonin gene-related peptide (CGRP) antagonist nominated for preclinical studies for migraine.

M2 EQUITYBITES-May 18, 2017-Heptares Therapeutics' calcitonin gene-related peptide (CGRP) antagonist nominated for preclinical studies for migraine

(C)2017 M2 COMMUNICATIONS http://www.m2.com

Heptares Therapeutics stated on Thursday that its preclinical candidate calcitonin gene-related peptide (CGRP) antagonist in partnership with Teva has been nominated for advancement into further preclinical studies as an investigational treatment for migraine.

Migraine is the recurring attacks of moderate to severe headache pain and is typically one-sided, throbbing and worse with activity.

Under the terms of the licensing and drug-discovery agreement, the nomination of this small-molecule candidate has triggered a USD5m payment from Teva to Heptares

This small-molecule candidate was discovered by Heptares using its structure-based design approach in partnership with Teva. The nominated compound emerged from a rigorous Teva candidate selection process and has a highly differentiated profile from other investigational small-molecule CGRP antagonists, representing the first milestone in a partnership to generate novel candidates for the treatment of episodic and chronic migraine.

According to the companies, Calcitonin gene-related peptide (CGRP) is released during migraine attacks and can trigger migraine in patients. CGRP is found in small to medium-sized neurons in the trigeminal ganglion and mediates its activity through G protein-coupled receptors located throughout the body. Elevated levels of CGRP are found in people with migraine during an attack and blocking CGRP activity is a validated mechanism of action for relieving pain, and also for preventing migraine.

Heptares is a clinical-stage company and part of Sosei Group Corporation (TSE Mothers Index:4565), a biopharmaceutical company originating from Japan.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:May 18, 2017
Words:265
Previous Article:Africa Oil Corp reports on oil discovery in Emekuya -1 Well in Kenya.
Next Article:Fuze recognized for excellence in demand creation, lead management.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters